For pharmaceutical companies seeking marketing authorization in Europe, proving safety and efficacy is only part of the equation. Today, every submission to the European Medicines Agency (EMA) or national competent authorities must also demonstrate that the medicinal product does not pose an unacceptable environmental risk.
What was once viewed as a secondary regulatory checkbox has evolved...
0 Commenti
0 condivisioni
100 Views
0 Anteprima
Nguza AI Social Earning Marketplacehttps://nguza.com